The HAS-BLED score for predicting major bleeding risk in anticoagulated patients with atrial fibrillation: A systematic review and meta-analysis

Clinical Cardiology

Volumn 38, Issue 9, 2015, Pages 555-561

  Zhu, Wengen ^a   He, Wenfeng ^a   Guo, Linjuan ^a   Wang, Xixing ^a   Hong, Kui ^a,b  

^a NANCHANG UNIVERSITY   (China)

^b Jiangxi Key Laboratory of Molecular Medicine   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K;

ANTICOAGULANT THERAPY; ANTICOAGULATION AND RISK FACTORS IN ATRIAL FIBRILLATION; ATRIAL FIBRILLATION; BLEEDING; CALIBRATION; CARDIOVASCULAR DISEASE ASSESSMENT; CEREBROVASCULAR ACCIDENT; CHA2DS2 VASC; CHADS2 SCORE; COMPARATIVE STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; HAS BLED SCORE; HEMORR2HAGES; HUMAN; PREDICTION; REVIEW; RISK ASSESSMENT; STATISTICAL ANALYSIS; SYSTEMATIC REVIEW; AGED; BLOOD; BLOOD CLOTTING; CHEMICALLY INDUCED; CHI SQUARE DISTRIBUTION; DECISION SUPPORT SYSTEM; DRUG EFFECTS; FEMALE; MALE; META ANALYSIS; MIDDLE AGED; ODDS RATIO; PATIENT SELECTION; PREDICTIVE VALUE; RISK FACTOR; TREATMENT OUTCOME;

AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; BLOOD COAGULATION; CHI-SQUARE DISTRIBUTION; DECISION SUPPORT TECHNIQUES; FEMALE; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 84942574251     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.22435     Document Type: Review

References (31)

1. Lloyd-Jones D, Adams RJ, Brown TM, et al., Executive summary: heart disease and stroke statistics-2010 update: a report from the American Heart Association [published correction appears in Circulation. 2010;121:e259]. Circulation. 2010; 121: 948-954.
2. Camm AJ, Lip GY, De Caterina R, et al., 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation-developed with the special contribution of the European Heart Rhythm Association. Europace. 2012; 14: 1385-1413.
3. Singer DE, Chang Y, Fang MC, et al., The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med. 2009; 151: 297-305.
4. Gorin L, Fauchier L, Nonin E, et al., Prognosis and guideline-adherent antithrombotic treatment in patients with atrial fibrillation and atrial flutter: implications of undertreatment and overtreatment in real-life clinical practice: the Loire Valley Atrial Fibrillation Project. Chest. 2011; 140: 911-917.
5. Gage BF, Yan Y, Milligan PE, et al., Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J. 2006; 151: 713-719.
6. Pisters R, Lane DA, Nieuwlaat R, et al., A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010; 138: 1093-1100.
7. Fang MC, Go AS, Chang Y, et al., A new risk scheme to predict warfarin-associated hemorrhage: the ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J Am Coll Cardiol. 2011; 58: 395-401.
8. Skanes AC, Healey JS, Cairns JA, et al., Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control [published correction appears in Can J Cardiol. 2012;28:396]. Can J Cardiol. 2012; 28: 125-136.
9. Whiting PF, Rutjes AW, Westwood ME, et al., QUADAS-2 Group. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011; 155: 529-536.
10. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, et al., Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med. 2008; 27: 157-172, 207-212.
11. Lip GY, Frison L, Halperin JL, et al., Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal renal/liver function, Stroke, Bleeding history or predisposition, Labile INR, Elderly, Drugs/alcohol concomitantly) score. J Am Coll Cardiol. 2011; 57: 173-180.
12. Gallego P, Roldán V, Torregrosa JM, et al., Relation of the HAS-BLED bleeding risk score to major bleeding, cardiovascular events, and mortality in anticoagulated patients with atrial fibrillation. Circ Arrhythm Electrophysiol. 2012; 5: 312-318.
13. Apostolakis S, Lane DA, Guo Y, et al., Performance of the HEMORR(2)HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in patients with atrial fibrillation undergoing anticoagulation: the AMADEUS (evaluating the use of SR34006 compared to warfarin or acenocoumarol in patients with atrial fibrillation) study. J Am Coll Cardiol. 2012; 60: 861-867.
14. Naganuma M, Shiga T, Sato K, et al., Clinical outcome in Japanese elderly patients with non-valvular atrial fibrillation taking warfarin: a single-center observational study. Thromb Res. 2012; 130: 21-26.
15. Friberg L, Rosenqvist M, Lip GY,. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J. 2012; 33: 1500-1510.
16. Apostolakis S, Lane DA, Buller H, et al., Comparison of the CHADS2, CHA2DS2-VASc and HAS-BLED scores for the prediction of clinically relevant bleeding in anticoagulated patients with atrial fibrillation: the AMADEUS trial. Thromb Haemost. 2013; 110: 1074-1079.
17. Roldán V, Marín F, Fernández H, et al., Predictive value of the HAS-BLED and ATRIA bleeding scores for the risk of serious bleeding in a "real-world" population with atrial fibrillation receiving anticoagulant therapy. Chest. 2013; 143: 179-184.
18. Roldán V, Marín F, Manzano-Fernández S, et al., The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation. J Am Coll Cardiol. 2013; 62: 2199-2204.
19. Barnes GD, Gu X, Haymart B, et al., The predictive ability of the CHADS2 and CHA2DS2-VASc scores for bleeding risk in atrial fibrillation: the MAQI(2) experience. Thromb Res. 2014; 134: 294-299.
20. Roger VL, Go AS, Lloyd-Jones DM, et al., Heart disease and stroke statistics-2012 update: a report from the American Heart Association [published correction appears in Circulation. 2012;125:e1002]. Circulation. 2012; 125: e2-e220.
21. Wang Y, Bajorek B,. Safe use of antithrombotics for stroke prevention in atrial fibrillation: consideration of risk assessment tools to support decision-making. Ther Adv Drug Saf. 2014; 5: 21-37.
22. Apostolakis S, Lane DA, Guo Y, et al., Performance of the HEMORR(2)HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in nonwarfarin anticoagulated atrial fibrillation patients. J Am Coll Cardiol. 2013; 61: 386-387.
23. Nieuwlaat R, Capucci A, Lip GY, et al., Euro Heart Survey Investigators. Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on Atrial Fibrillation. Eur Heart J. 2006; 27: 3018-3026.
24. Corbanese U., Assessing the performance of the HAS-BLED score: is the C statistic sufficient? Chest. 2011; 139: 1247-1248.
25. Caldeira D, Costa J, Fernandes RM, et al., Performance of the HAS-BLED high bleeding-risk category, compared to ATRIA and HEMORR2HAGES in patients with atrial fibrillation: a systematic review and meta-analysis. J Interv Card Electrophysiol. 2014; 40: 277-284.
26. Lip GY, Banerjee A, Lagrenade I, et al., Assessing the risk of bleeding in patients with atrial fibrillation: the Loire Valley Atrial Fibrillation Project. Circ Arrhythm Electrophysiol. 2012; 5: 941-948.
27. Kamran SH, Muzammil SM, Kamal AK,. Is HAS-BLED score better than CHADS2 and HEMOR2RHAGES schemes in assessing 1 year risk of major bleed in atrial fibrillation patients? J Pak Med Assoc. 2013; 63: 281-282.
28. Dzeshka MS, Lane DA, Lip GY,. Stroke and bleeding risk in atrial fibrillation: navigating the alphabet soup of risk-score acronyms (CHADS2, CHA2DS2-VASc, R2 CHADS2, HAS-BLED, ATRIA, and more). Clin Cardiol. 2014; 37: 634-644.
29. De Caterina R, Husted S, Wallentin L, et al., Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease. Thromb Haemost. 2013; 110: 1087-1107.
30. Thomas IC, Sorrentino MJ,. Bleeding risk prediction models in atrial fibrillation. Curr Cardiol Rep. 2014; 16: 432.
31. Gallego P, Roldán V, Marín F, et al., Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation. Thromb Haemost. 2013; 110: 1189-1198.